Aditya A Joshi1, Joseph B Lerman1, Tsion M Aberra1, Mehdi Afshar1, Heather L Teague1, Justin A Rodante1, Parasuram Krishnamoorthy1, Qimin Ng1, Tarek Z Aridi1, Taufiq Salahuddin1, Balaji Natarajan1, Benjamin N Lockshin1, Mark A Ahlman1, Marcus Y Chen1, Daniel J Rader1, Muredach P Reilly1, Alan T Remaley1, David A Bluemke1, Martin P Playford1, Joel M Gelfand1, Nehal N Mehta2. 1. From the Cardiovascular and Pulmonary Branch (A.A.J., J.B.L., T.M.A., H.L.T., J.A.R., Q.N., T.Z.A., T.S., B.N., M.Y.C., A.T.R., D.A.B., M.P.P., N.N.M.), Section of Inflammation and Cardiometabolic Diseases (A.A.J., J.B.L., T.M.A., H.L.T., J.A.R., Q.N., T.Z.A., T.S., B.N., A.T.R., M.P.P., N.N.M.), National Heart, Lung, and Blood Institute, Bethesda, MD; Department of Internal Medicine, Allegheny General Hospital, Pittsburgh, PA (A.A.J.); Department of Medicine, McGill University, Montreal, QC, Canada (M.A.); Department of Cardiology, Einstein Institute for Heart and Vascular Health, Albert Einstein Medical Center, Philadelphia, PA (P.K.); Department of Internal Medicine, University of Colorado, Denver (T.S.); Department of Internal Medicine, University of Arizona College of Medicine at South Campus, Tucson (B.N.); Derm Associates, Silver Spring, MD (B.N.L.); Department of Radiology and Imaging Sciences, National Institutes of Health Clinical Research Center, Bethesda, MD (M.A.A.); Perelman School of Medicine (D.J.R.), Department of Dermatology (J.M.G.), and The Center for Clinical Epidemiology and Biostatistics (J.M.G.), University of Pennsylvania, Philadelphia; and Division of Cardiology, Department of Medicine, Irving Institute for Clinical and Translational Research, Columbia University, New York (M.P.R.). 2. From the Cardiovascular and Pulmonary Branch (A.A.J., J.B.L., T.M.A., H.L.T., J.A.R., Q.N., T.Z.A., T.S., B.N., M.Y.C., A.T.R., D.A.B., M.P.P., N.N.M.), Section of Inflammation and Cardiometabolic Diseases (A.A.J., J.B.L., T.M.A., H.L.T., J.A.R., Q.N., T.Z.A., T.S., B.N., A.T.R., M.P.P., N.N.M.), National Heart, Lung, and Blood Institute, Bethesda, MD; Department of Internal Medicine, Allegheny General Hospital, Pittsburgh, PA (A.A.J.); Department of Medicine, McGill University, Montreal, QC, Canada (M.A.); Department of Cardiology, Einstein Institute for Heart and Vascular Health, Albert Einstein Medical Center, Philadelphia, PA (P.K.); Department of Internal Medicine, University of Colorado, Denver (T.S.); Department of Internal Medicine, University of Arizona College of Medicine at South Campus, Tucson (B.N.); Derm Associates, Silver Spring, MD (B.N.L.); Department of Radiology and Imaging Sciences, National Institutes of Health Clinical Research Center, Bethesda, MD (M.A.A.); Perelman School of Medicine (D.J.R.), Department of Dermatology (J.M.G.), and The Center for Clinical Epidemiology and Biostatistics (J.M.G.), University of Pennsylvania, Philadelphia; and Division of Cardiology, Department of Medicine, Irving Institute for Clinical and Translational Research, Columbia University, New York (M.P.R.). nehal.mehta@nih.gov.
Abstract
RATIONALE: GlycA, an emerging inflammatory biomarker, predicted cardiovascular events in population-based studies. Psoriasis, an inflammatory disease associated with increased cardiovascular risk, provides a model to study inflammatory biomarkers in cardiovascular disease (CVD). Whether GlycA associates with psoriasis and how it predicts subclinical CVD beyond high-sensitivity C-reactive protein in psoriasis is unknown. OBJECTIVE: To investigate the relationships between GlycA and psoriasis and between GlycA and subclinical CVD. METHODS AND RESULTS: Patients with psoriasis and controls (n=412) participated in a 2-stage study. We measured GlycA by nuclear magnetic resonance spectroscopy. National Institutes of Health (NIH) participants underwent 18-F Fluorodeoxyglucose Positron Emission Tomography Computed Tomography (18-FDG PET/CT) scans to assess vascular inflammation (VI) and coronary computed tomographic angiography to quantify coronary artery disease burden. Psoriasis cohorts were young (mean age=47.9), with low cardiovascular risk and moderate skin disease. high-sensitivity C-reactive protein and GlycA were increased in psoriasis compared with controls (GlycA: [PENN: 408.8±75.4 versus 289.4±60.2, P<0.0001; NIH: 415.8±63.2 versus 346.2±46, P<0.0001]) and demonstrated a dose-response with psoriasis severity. In stage 2, VI (β=0.36, P<0.001) and coronary artery disease (β=0.29, P=0.004) associated with GlycA beyond CV risk factors in psoriasis. In receiver operating characteristic analysis, GlycA added value in predicting VI (P=0.01) and coronary artery disease (P<0.01). Finally, initiating anti-tumor necrosis factor therapy (n=16) reduced psoriasis severity (P<0.001), GlycA (463.7±92.5 versus 370.1±78.5, P<0.001) and VI (1.93±0.36 versus 1.76±0.19, P<0.001), whereas GlycA remained associated with VI (β=0.56, P<0.001) post treatment. CONCLUSIONS: GlycA associated with psoriasis severity and subclinical CVD beyond traditional CV risk and high-sensitivity C-reactive protein. Moreover, psoriasis treatment reduced GlycA and VI. These findings support the potential use of GlycA in subclinical CVD risk assessment in psoriasis and potentially other inflammatory diseases.
RATIONALE: GlycA, an emerging inflammatory biomarker, predicted cardiovascular events in population-based studies. Psoriasis, an inflammatory disease associated with increased cardiovascular risk, provides a model to study inflammatory biomarkers in cardiovascular disease (CVD). Whether GlycA associates with psoriasis and how it predicts subclinical CVD beyond high-sensitivity C-reactive protein in psoriasis is unknown. OBJECTIVE: To investigate the relationships between GlycA and psoriasis and between GlycA and subclinical CVD. METHODS AND RESULTS:Patients with psoriasis and controls (n=412) participated in a 2-stage study. We measured GlycA by nuclear magnetic resonance spectroscopy. National Institutes of Health (NIH) participants underwent 18-F Fluorodeoxyglucose Positron Emission Tomography Computed Tomography (18-FDG PET/CT) scans to assess vascular inflammation (VI) and coronary computed tomographic angiography to quantify coronary artery disease burden. Psoriasis cohorts were young (mean age=47.9), with low cardiovascular risk and moderate skin disease. high-sensitivity C-reactive protein and GlycA were increased in psoriasis compared with controls (GlycA: [PENN: 408.8±75.4 versus 289.4±60.2, P<0.0001; NIH: 415.8±63.2 versus 346.2±46, P<0.0001]) and demonstrated a dose-response with psoriasis severity. In stage 2, VI (β=0.36, P<0.001) and coronary artery disease (β=0.29, P=0.004) associated with GlycA beyond CV risk factors in psoriasis. In receiver operating characteristic analysis, GlycA added value in predicting VI (P=0.01) and coronary artery disease (P<0.01). Finally, initiating anti-tumornecrosis factor therapy (n=16) reduced psoriasis severity (P<0.001), GlycA (463.7±92.5 versus 370.1±78.5, P<0.001) and VI (1.93±0.36 versus 1.76±0.19, P<0.001), whereas GlycA remained associated with VI (β=0.56, P<0.001) post treatment. CONCLUSIONS:GlycA associated with psoriasis severity and subclinical CVD beyond traditional CV risk and high-sensitivity C-reactive protein. Moreover, psoriasis treatment reduced GlycA and VI. These findings support the potential use of GlycA in subclinical CVD risk assessment in psoriasis and potentially other inflammatory diseases.
Authors: Akintunde O Akinkuolie; Aruna D Pradhan; Julie E Buring; Paul M Ridker; Samia Mora Journal: Arterioscler Thromb Vasc Biol Date: 2015-04-23 Impact factor: 8.311
Authors: Nehal N Mehta; Parasuram Krishnamoorthy; YiDing Yu; Omar Khan; Anna Raper; Abby Van Voorhees; Andrea B Troxel; Joel M Gelfand Journal: J Am Acad Dermatol Date: 2012-06-26 Impact factor: 11.527
Authors: O Ahlehoff; G H Gislason; M Charlot; C H Jørgensen; J Lindhardsen; J B Olesen; S Z Abildstrøm; L Skov; C Torp-Pedersen; P R Hansen Journal: J Intern Med Date: 2010-11-29 Impact factor: 8.989
Authors: James D Otvos; Irina Shalaurova; Justyna Wolak-Dinsmore; Margery A Connelly; Rachel H Mackey; James H Stein; Russell P Tracy Journal: Clin Chem Date: 2015-03-16 Impact factor: 8.327
Authors: Axel Rominger; Tobias Saam; Sarah Wolpers; Clemens C Cyran; Michael Schmidt; Stefan Foerster; Konstantin Nikolaou; Maximilian F Reiser; Peter Bartenstein; Marcus Hacker Journal: J Nucl Med Date: 2009-09-16 Impact factor: 10.057
Authors: Mathijs O Versteylen; Bas L Kietselaer; Pieter C Dagnelie; Ivo A Joosen; Admir Dedic; Rolf H Raaijmakers; Joachim E Wildberger; Koen Nieman; Harry J Crijns; Wiro J Niessen; Mat J Daemen; Leonard Hofstra Journal: J Am Coll Cardiol Date: 2013-04-03 Impact factor: 24.094
Authors: James D Otvos; John R Guyton; Margery A Connelly; Sydney Akapame; Vera Bittner; Steven L Kopecky; Megan Lacy; Santica M Marcovina; Joseph B Muhlestein; William E Boden Journal: J Clin Lipidol Date: 2018-01-12 Impact factor: 4.766
Authors: Angelica Ezeigwe; Oluwaseun E Fashanu; Di Zhao; Matthew J Budoff; James D Otvos; Isac C Thomas; Samia Mora; Martin Tibuakuu; Erin D Michos Journal: Atherosclerosis Date: 2019-01-24 Impact factor: 5.162
Authors: Joseph B Lerman; Aditya A Joshi; Abhishek Chaturvedi; Tsion M Aberra; Amit K Dey; Justin A Rodante; Taufiq Salahuddin; Jonathan H Chung; Anshuma Rana; Heather L Teague; Jashin J Wu; Martin P Playford; Benjamin A Lockshin; Marcus Y Chen; Veit Sandfort; David A Bluemke; Nehal N Mehta Journal: Circulation Date: 2017-05-08 Impact factor: 29.690
Authors: Charlotte L Harrington; Amit K Dey; Raza Yunus; Aditya A Joshi; Nehal N Mehta Journal: Am J Physiol Heart Circ Physiol Date: 2017-03-03 Impact factor: 4.733
Authors: Sunyoung Jang; Oluseye Ogunmoroti; Chiadi E Ndumele; Di Zhao; Vishal N Rao; Oluwaseun E Fashanu; Martin Tibuakuu; James D Otvos; Eve-Marie Benson; Pamela Ouyang; Erin D Michos Journal: Circ Heart Fail Date: 2020-07-28 Impact factor: 8.790
Authors: Nehal N Mehta; Daniel B Shin; Aditya A Joshi; Amit K Dey; April W Armstrong; Kristina Callis Duffin; Zelma Chiesa Fuxench; Charlotte L Harrington; Rebecca A Hubbard; Robert E Kalb; Alan Menter; Daniel J Rader; Muredach P Reilly; Eric L Simpson; Junko Takeshita; Drew A Torigian; Thomas J Werner; Andrea B Troxel; Stephen K Tyring; Suzette Baez Vanderbeek; Abby S Van Voorhees; Martin P Playford; Mark A Ahlman; Abass Alavi; Joel M Gelfand Journal: Circ Cardiovasc Imaging Date: 2018-06 Impact factor: 7.792
Authors: Milena Aksentijevich; Sundus S Lateef; Paula Anzenberg; Amit K Dey; Nehal N Mehta Journal: Trends Cardiovasc Med Date: 2019-11-20 Impact factor: 6.677
Authors: Aditya A Joshi; Joseph B Lerman; Amit K Dey; Aparna P Sajja; Agastya D Belur; Youssef A Elnabawi; Justin A Rodante; Tsion M Aberra; Jonathan Chung; Taufiq Salahuddin; Balaji Natarajan; Jenny Dave; Aditya Goyal; Jacob W Groenendyk; Joshua P Rivers; Yvonne Baumer; Heather L Teague; Martin P Playford; David A Bluemke; Mark A Ahlman; Marcus Y Chen; Joel M Gelfand; Nehal N Mehta Journal: JAMA Cardiol Date: 2018-10-01 Impact factor: 14.676